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ABSTRACT
Insufﬁciency of 25-hydroxyvitaminD [25(OH)D] is highly preva-
lent among patients with chronic kidney disease (CKD) or end-
stage renaldisease (ESRD)and is acritical component in thepatho-
genesis of secondary hyperparathyroidism. Accordingly, current
National Kidney Foundation—Kidney Disease Outcomes Quality
Initiative andKidneyDisease: ImprovingGlobalOutcomes guide-
lines recommend thecorrectionofhypovitaminosisD throughnu-
tritional vitaminDreplacementas aﬁrst-step therapeutic approach
targeting secondary hyperparathyroidism. In this Polar Views de-
bate,wesummarize theexistingevidence,aimingtodefendthepos-
ition that nutritional vitaminD replacement is not evidence-based
and should not be applied to patients with CKD. This position is
supported by the following: (i) our meta-analysis of randomized
controlled trials shows that whereas nutritional vitamin D signiﬁ-
cantly increases serum 25(OH)D levels relative to placebo, there
is no evidence either in predialysis CKD or in ESRD that parathy-
roid hormone (PTH) is lowered; (ii) on the other hand, in rando-
mized head-to-head comparisons, nutritional vitamin D is
shown to be inferior to activated vitamin D analogs in reducing
PTH levels; (iii) nutritional vitaminD is reported to exertminimal
tonobeneﬁcial actions inaseriesof surrogate risk factors, including
aortic stiffness, left ventricularmass index (LVMI), epoetin utiliza-
tion and immune function among others; and (iv) there is no evi-
dence to support a beneﬁt of nutritional vitaminDon survival and
other ‘hard’ clinical outcomes. Whereas nutritional vitamin D re-
placement may restore 25(OH)D concentration to near normal,
the real target of treating vitaminD insufﬁciency is to treat second-
ary hyperparathyroidism, which is untouched by nutritional vita-
min D. Furthermore, the pleotropic beneﬁts of nutritional
vitamin D remain to be proven. Thus, there is little, if any, beneﬁt
of nutritional vitamin D replacement in CKD.
Keywords: cholecalciferol, CKD, nutritional vitamin D,
secondary hyperparathyroidism
INTRODUCTION
Among people with chronic kidney disease (CKD) or end-stage
renal disease (ESRD), 25-hydroxyvitamin D [25(OH)D] insuf-
ﬁciency or deﬁciency is common and has been proposed to
contribute to the pathogenesis of secondary hyperparathyroid-
ism and other alterations related to the CKD–mineral and bone
disorder (CKD-MBD) [1–3]. The National Kidney Foundation
—Kidney Disease Outcomes Quality Initiative (NKF-KDOQI)
[4] and Kidney Disease: Improving Global Outcomes (KDIGO)
[1] guidelines recognize the potential role of low serum 25(OH)
D levels and both guidelines recommended that 25(OH)D de-
ﬁciency or insufﬁciency should be corrected as a ﬁrst-step
therapeutic approach targeting secondary hyperparathyroidism
in people with non-dialysis-requiring CKD; no such recom-
mendation was provided for people with ESRD. If this approach
is ineffective, then guidelines recommend the utilization of vita-
min D receptor activators (VDRAs) [1, 4]. The use of nutrition-
al vitamin D supplements in CKD and ESRD is an issue
surrounded by substantial controversy, given that
NKF-KDOQI and KDIGO recommendations were based
mainly on expert opinion instead of supporting evidence
from properly designed, randomized controlled trials (RCTs)
[2].
In this Polar Views debate, we review the existing evidence,
aiming to support the position that the use of nutritional vita-
min D supplementation has little or no beneﬁcial effect in the
management of people with CKD, including ESRD. We con-
clude that the scientiﬁc basis of the use of nutritional vitamin
D among people with CKD and ESRD rests on weak evidence.
OBSERVATIONAL EVIDENCE
Over the past years, numerous observational studies conducted
in CKD and ESRD populations have associated low serum
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25(OH)D with higher parathyroid hormone (PTH) levels and
various adverse health-related outcomes, such as acceleration of
vascular calciﬁcations, higher incidence of bone fractures, early
glomerular ﬁltration rate loss, faster CKD progression and in-
creased risk of cardiovascular morbidity and mortality [5–10].
A previous meta-analysis of 10 prospective observational stud-
ies with an overall sample of 6853 CKD patients suggested that
each 10 ng/mL increase in serum 25(OH)D levels is associated
with a 14% reduction in the risk of all-cause mortality [relative
risk (RR): 0.86; 95% conﬁdence interval (CI): 0.83–0.91] [11].
Another meta-analysis by Kandula et al. [12] including 17 non-
randomized interventional studies suggested that among those
with CKD, nutritional vitamin D can successfully restore serum
25(OH)D levels [mean difference (MD): 24.1 ng/mL; 95% CI:
19.6–28.6], exerting in parallel a signiﬁcant PTH-lowering ef-
fect (MD: −47.1 pg/mL; 95% CI: −55.8 to −27.7). However,
these positive effects should be interpreted within the context
of the inherent methodological limitations of the individual
studies included in this meta-analysis; these studies were obser-
vational in nature and of low-to-moderate quality [12]. Al-
though the observational evidence seems to be positive,
causality between nutritional vitamin D replacement and im-
provement in outcomes cannot be established through observa-
tional association studies. Observational studies are rife in
nephrology and often used to make guidelines. However, with-
out properly designed, RCTs we cannot fully elucidate whether
nutritional vitamin D has a role in people with CKD. We will
therefore review the randomized evidence next, to explore the
possibility of whether nutritional vitamin D is valuable in CKD.
RANDOMIZED EVIDENCE
Effect of nutritional vitamin D on 25(OH)D status and
PTH levels
A previous meta-analysis of ﬁve RCTs comparing the effects
of nutritional vitaminDwith placebo suggested a signiﬁcant in-
crease in serum 25(OH)D levels with cholecalciferol or ergocal-
ciferol supplementation (MD: 13.9 ng/mL; 95% CI: 5.6–22.4);
restoration of vitamin D status was shown to be accompanied
by a modest, but statistically signiﬁcant reduction in PTH levels
(MD: −32.5 pg/mL; 95% CI: −57.0 to −6.1) [12]. This meta-
analysis was published in 2010 and combined data from only
three available RCTs reporting data on 25(OH)D (71 patients)
and only four RCTs reporting data on PTH levels (90 patients)
[12]. From that time-point and onwards, additional rando-
mized evidence has accumulated. To provide a more conclusive
answer to the question of whether nutritional vitamin D has a
role in management of secondary hyperparathyroidism among
people with CKD, we performed an updated meta-analysis of
the currently available evidence on these two outcomes.
As shown in Figure 1, we identiﬁed 4 RCTs including 130
CKD participants not yet on dialysis [13–16] and 14 RCTs
including 888 ESRD participants on maintenance dialysis
[16–28] that compared inactive vitamin D with placebo and re-
ported data on serum 25(OH)D levels. The study of Marck-
mann et al. [16] is reported twice in Figure 1, because this
study included patients with stage 3–5D CKD; accordingly,
the outcome of 25(OH)D was analyzed separately for predialy-
sis CKD and ESRD subgroups. In predialysis CKD, the
weighted MD in the change of 25(OH)D levels during follow-
up between nutritional vitamin D and placebo groups was
12.5 ng/mL (95% CI: 8.48–16.52) using an inverse-weighted,
ﬁxed-effect model and 21.19 ng/mL (95% CI: 8.87–33.51)
using a random-effects model. In ESRD, the weighted MD in
change of 25(OH)D between nutritional vitamin D and placebo
groups was 16.01 ng/mL (95% CI: 13.31–18.71) using an
inverse-weighted, ﬁxed-effect model and 20.89 ng/mL (95%
CI: 15.76–26.03) using a random-effects model. There was no
evidence of heterogeneity between CKD and ESRD subgroups
(P = 0.156).
With regards to the pooled PTH-lowering effect of nutri-
tional vitamin D, we identiﬁed four RCTs including 122 predia-
lysis CKD participants [14–16, 29] and seven RCTs including
568 ESRD participants on dialysis [17, 20, 22, 24, 25, 27, 28]
that reported data on PTH levels (Figure 2). In predialysis
CKD, the weighted MD in the change of PTH levels during
follow-up between nutritional vitamin D and placebo groups
was not signiﬁcant either using an inverse-weighted,
ﬁxed-effects model (MD: −4.01 pg/mL; 95% CI: −26.67 to
18.65) or using a random-effects model (MD: −28.22 pg/mL;
95% CI: −105.8 to 49.35). Consistent with the above observa-
tion, in ESRD, nutritional vitamin D did not signiﬁcantly im-
prove PTH levels as compared with placebo either when an
inverse-weighted, ﬁxed-effects model (MD: −24.43 pg/mL;
95% CI: −53.27 to 4.42) or when a random-effects model was
used (MD: −25.33 pg/mL; 95% CI: −57.28 to 6.62). There was
no evidence of heterogeneity between the predialysis CKD and
ESRD subgroups (P = 0.275). In contrast to the smaller earlier
meta-analysis, the above data suggest that a signiﬁcant
PTH-lowering effect with inactive vitamin D is supported nei-
ther in the predialysis CKD nor in the ESRD setting.
Nutritional vitamin D versus vitamin D receptor
activators for PTH-lowering
VDRAs such as paricalcitol or doxercalciferol have been ap-
proved by the US FDA for the prevention or treatment or both
of secondary hyperparathyroidism in CKD. Thus, their value in
treating these conditions in those with CKD is ﬁrmly estab-
lished using rigorous double-blind RCTs [30–32]. However,
head-to-head comparisons with nutritional vitamin D are few.
In a single-blind randomized trial, Moe et al. [33] performed
a head-to-head comparison between cholecalciferol (4000 IU/
day for 1 month and then 2000 IU/day for the next 2 months,
n = 22) and the active vitamin D analog doxercalciferol
(1 μg/day, n = 25) in 47 vitamin D deﬁcient patients with
stage 3–4 CKD and secondary hyperparathyroidism. After 3
months of therapy, a signiﬁcant reduction in PTH levels of
27 ± 34% (P = 0.002) was noted in the active vitamin D
group, and a non-signiﬁcant reduction of 10 ± 31% (P = 0.16)
in the cholecalciferol group; the between-group difference in
the proportional change of PTH was not signiﬁcant (P = 0.11),
possibly due to the small sample size. A signiﬁcant increase of
23 ng/mL in serum 25(OH)D levels from pre- to post-
treatment (P < 0.001) was noted in cholecalciferol-treated pa-
tients, but not in those treated with doxercalciferol [33].
P
O
L
A
R
V
IE
W
S
IN
N
E
P
H
R
O
L
O
G
Y
N u t r i t i o n a l v i t a m i n D r e p l a c e m e n t i n C K D a n d E S R D 707
 at Indiana U
niversity School of M
edicine Libraries on D
ecem
ber 6, 2016
http://ndt.oxfordjournals.org/
D
ow
nloaded from
 
Kovesdy et al. [34] randomized 80 stage 3–4 CKD patients
with vitamin D deﬁciency and secondary hyperparathyroidism
to ergocalciferol (50 000 IU weekly-to-monthly) or paricalcitol
(1–2 μg/day) for 4 months. Ergocalciferol was shown to be in-
ferior to active vitamin D in causing PTH reduction, since the
proportion of patients reaching the primary study endpoint
(deﬁned as the occurrence of two consecutive PTH levels de-
creased by at least 30% from baseline) was signiﬁcantly lower
in ergocalciferol-treated than in paricalcitol-treated partici-
pants (18 versus 58%, P = 0.002) [34]. To the extent that this
inferiority is true, the use of nutritional vitamin D in CKD is
not only ineffective, but may also result in delayed institution
of other effective therapies against secondary hyperparathyr-
oidism, such as activated vitamin D analogs.
Effects of nutritional vitamin D on non-mineral-related
intermediate endpoints
Vitamin D has numerous non-calcemic effects such as vas-
cular effects, immunomodulatory effects, anti-inﬂammatory ef-
fects, suppression of the renin-angiotensin system, and effects
on glucose homeostasis [35]. Therefore, it should not be sur-
prising that numerous investigators have tested the non-
calcemic beneﬁts of vitamin D supplementation among people
with CKD.
We discuss further that nutritional vitamin D has minimal
to no beneﬁcial actions on these endpoints. Effects on a series of
intermediate outcomes reported in RCTs, the so-called pleotro-
pic effects, are summarized in Table 1 and discussed in detail
below.
Pulse wave velocity and left ventricular mass index. In a
double-blind manner, Marckmann et al. [16] randomized 52
patients with stage 3–5D CKD to cholecalciferol (40 000 IU
weekly) or placebo. Over a 2-month-long follow-up, changes
in aortic pulse wave velocity (PWV) were comparable in both
vitaminD and placebo; this effect was consistent in both predia-
lysis CKD and ESRD subgroups. In a subsequent study, Dreyer
et al. [29] investigated the effect of ergocalciferol (50 000 IU
weekly for 1 month and monthly later) versus placebo on
macro- and microcirculatory function. Over a 6-month follow-
up, change in aortic PWV and LVMI was no different between
groups. However, ergocalciferol signiﬁcantly improved
endothelium-dependent vasodilatation after iontophoresis of
acetylcholine, suggesting a beneﬁt on microcirculatory endo-
thelial function [29]. In contrast, in a larger RCT testing
F IGURE 1 : Forest plot depicting the change from baseline in 25(OH)D levels in the ‘nutritional vitaminD group’minus the change from baseline
in the ‘placebo group’.
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paricalcitol versus placebo, the endothelium-dependent vaso-
dilatation in patients with stage 3 and 4 CKD was improved
1.8% (95% CI: 0.3–3.1%, P = 0.016) [38].
As in the case of predialysis CKD,Mose et al. [25] showed that
among 64 ESRD patients receiving hemodialysis, 6-month-long
therapy with cholecalciferol (3000 IU/day) was unable to im-
prove aortic PWVand LVMI relative to placebo (ΔPWV: 0.8 ver-
sus 0.1 m/s, P = 0.269;ΔLVMI: 3 versus−5 g/m2, P = 0.397) [25].
In another study, Hewitt et al. [21] randomized 60 hemodialysis
patients with 25(OH)D deﬁciency to ergocalciferol (50 000 IU
weekly for 8 weeks and monthly later) or placebo for 6 months;
nutritional vitamin D was not superior to placebo in improving
aortic stiffness.
Anemia. The effect of nutritional vitamin D on epoetin util-
ization was investigated in the recently reported study of Mis-
kulin et al. [24], in which 276 hemodialysis patients with serum
25(OH)D levels <30 ng/mL were randomly assigned to receive
double-blind therapy with ergocalciferol (50 000 IU weekly) or
placebo. Nutritional vitamin D had no effect on anemia man-
agement over the 6-month follow-up, since rate of change in
epoetin dose over time was no different between the ergocal-
ciferol and placebo groups (geometric mean rate: 0.99; 95%
CI: 0.95–1.03) [24]. The effect of nutritional vitamin D on
anemia-related parameters was also reported in the Dialysis
Infection and Vitamin D in New England (DIVINE) trial
[19], in which 105 hemodialysis patients were randomized
to three different arms (ergocalciferol 50 000 IU/month,
ergocalciferol 50 000 IU/week or placebo). Frequency of
intravenous iron use (monthly 39% versus weekly 39% versus
placebo 51%, P = 0.49) and epoetin utilization (monthly 71%
versus weekly 69% versus placebo 60%, P = 0.61) were not
different between the three study arms [19].
Immune function. To investigate the effect of nutritional
vitamin D on immune function, Li et al. [22] randomized 96
hemodialysis patients in a 2:1 ratio to cholecalciferol (50 000
IU weekly) or no supplementation. Change in alloreactive
T-cell memory assessed by IFNγ ELISPOT-based panel of re-
active T-cell assays (PRT) was no different between groups
over the 12-month follow-up of the trial (ΔPRT: 104.8 ± 2330.8
versus 252.9 ± 2431.3, P = 0.25) [22]. In another double-blind
RCT, Seibert et al. [26] showed that administration of cholecal-
ciferol at a dose of 20 000 IU/week for 3 months had no beneﬁt
relative to placebo on monocyte subset cell count, T-cell differ-
entiation and cytokine production.
Other outcomes. In the aforementioned study of Hewitt et al.
[21], 6-month-long ergocalciferol supplementation did not im-
prove muscle strength tests, functional capacity and
health-related quality of life assessed with the use of the Kidney
Disease Quality of Life-36 survey. Two other small RCTs
F IGURE 2 : Forest plot depicting the change from baseline in PTH levels in the ‘nutritional vitamin D group’minus the change from baseline in
the ‘placebo group’.
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Table 1. Randomized studies comparing the effect of inactive vitamin D supplementation versus placebo or no treatment on surrogate risk factors in patients with CKD and ESRD
Author Year n Patient characteristics Design Intervention Control Duration
(months)
Outcome Overall
effect
Details
Studies in CKD patients
Marckmann [16] 2012 52 CKD stage 3–5D Double-blind Cholecalciferol (40 000 IU
weekly)
Placebo 2 Change in PWV Null PWV was unchanged over time
(ΔPWV: 0.7 versus −0.3 m/s,
P = NS)
Alvarez [36] 2013 46 CKD stage 2–3 Double-blind Cholecalciferol (50 000 IU
weekly for 12 weeks and
then 50 000 IU every other
week)
Placebo 12 Change in
inﬂammatory
biomarkers
Null Change in serum MCP-1 over
time was no different between
groups (−3.0 ± 14.5 versus
2.5 ± 13.2%, P = NS)
Dreyer [29] 2014 38 Stage 3–4 CKD with
25(OH)D <16 ng/mL
Double-blind Ergocalciferol (50 000 IU
weekly for 1 month and
monthly later)
Placebo 6 Change in micro- and
macrocirculatory
function
Null No effect on aortic PWV
(P = 0.78) and LVMI (P = 0.44)
Positive Ergocalciferol improved
endothelium-dependent
vasodilatation after
iontophoresis of acetylcholine
(P = 0.03)
Studies in ESRD patients
Delanaye [20] 2013 43 HD patients with 25(OH)
D insufﬁciency
Double-blind Cholecalciferol (25 000 IU
every 2 weeks)
Placebo 12 Change in vascular
calciﬁcation score
Null No difference between groups
in change of vascular
calciﬁcation score over time
(Deltas: 2 ± 3 versus 2 ± 2,
P = 0.89)
Hewitt [21] 2013 60 HD patients with 25(OH)
D <24 ng/mL
Double-blind Ergocalciferol (50 000 IU
weekly for 8 weeks and
monthly later)
Placebo 6 Change in muscle
strength, PWV and
HRQOL
Null Muscle strength tests, aortic
PWV and HRQOL domains
were no different between
groups
Seibert [26] 2013 38 HD patients with 25(OH)
D insufﬁciency
Double-blind Cholecalciferol (20 000 IU
weekly)
Placebo 3 Change in immune
function
Null Cholecalciferol had no beneﬁt
on monocyte subset cell count,
T cell differentiation and
cytokine production relative to
placebo
Mose [25] 2014 64 HD patients with 25(OH)
D insufﬁciency
Double-blind Cholecalciferol (3000 IU
daily)
Placebo 6 Change in PWV and
LVMI
Null No difference between groups
in change of aortic PWV
(Deltas: 0.8 versus 0.1 m/s,
P = 0.269) and LVMI (Deltas: 3
versus −5 g/m2, P = 0.397) over
time
Li [22] 2014 96 HD patients with 25(OH)
D <20 ng/mL
Open-label Cholecalciferol (50 000 IU
weekly)
Nothing 12 Change in immune
function
Null Change in alloreactive T-cell
memory assessed by IFNγ
ELISPOT-based panel of
reactive T-cell assays did not
differ between groups (Deltas:
104.8 ± 2330.8 versus
252.9 ± 2431.3, P = 0.25)
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showed that compared with placebo, nutritional vitamin D had
no beneﬁt on bone mass density [37] and vascular calciﬁcation
score [20] among hemodialysis patients.
Effect of nutritional vitamin D on survival and clinical
outcomes
The effect of nutritional vitamin D on all-cause and cause-
speciﬁcmorbidity andmortality remains unclear, due to the ab-
sence of adequately powered RCTs to evaluate survival and
other ‘hard’ clinical outcomes as primary trial endpoints. Avail-
able data on clinical outcomes are derived from the study of
Miskulin and co-workers, the largest RCT conduced so far, in
which the incidence of all-cause hospitalizations [incidence rate
ratio (IRR): 0.82; 95% CI: 0.60–1.12], cardiovascular disease
hospitalizations (IRR: 0.60; 95% CI: 0.33–1.09) and infection-
related hospitalizations (IRR: 1.03; 95% CI: 0.50–2.10) over
the 6-month follow-up did not signiﬁcantly differ between
the ergocalciferol and placebo groups [24]. The authors state
in the paper, and we agree, that ‘estimates are imprecise given
the small sample size’ [24]. All-cause hospitalization and
survival data were also collected in the DIVINE trial [19]. Inci-
dence of all-cause hospitalizations over the 3-month treatment
period was similar in the three study arms (monthly ergocalcif-
erol: 11 events; weekly ergocalciferol: 14 events; placebo: 11
events, P = 0.89). Survival was assessed in an extended
12-month post-treatment follow-up; all-cause mortality was
no different between ergocalciferol-treated and placebo-treated
patients [hazard ratio (HR): 0.28; 95% CI: 0.07–1.19] [19].
Again, anHR as low as 0.28 together with thewide CIs indicates
that the study was underpowered to detect signiﬁcant differ-
ences between groups on survival.
In comparison, in the multinational, double-blind, rando-
mized placebo-controlled trial among 227 patients with CKD,
mild to moderate left ventricular hypertrophy, and preserved
left ventricular ejection fraction, conducted in 11 countries,
showed that the number of hospitalizations from any cause
(paricalcitol, 15.7% versus placebo, 17.0%; P = 0.86) and
from noncardiovascular causes (paricalcitol, 15.7% versus
placebo, 11.6%; P = 0.44) did not differ between groups [39].
In contrast, there were fewer hospitalizations for cardiovascu-
lar disease events in the paricalcitol group (placebo group 8.8
per 100 person years, paricalcitol group 1.1 per 100 person
years, P = 0.04). The most common cardiovascular event was
congestive heart failure (paricalcitol, n = 0; placebo, n = 5).
Thus, there is at least some evidence for beneﬁt with activated
vitamin D.
CONCLUSIONS
In conclusion, correction of hypovitaminosis D with the use of
nutritional vitamin D supplements in people with CKD and
ESRD is not justiﬁed by the currently available evidence for
the following reasons: (i) a meta-analysis of 11 RCTs compar-
ing cholecalciferol or ergocalciferol with placebo does support a
signiﬁcant PTH-lowering effect both in the predialysis CKD
and ESRD settings; (ii) RCTs comparing head-to-head nutri-
tional vitamin D supplements with VDRAs have shown that
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inactive vitamin D is inferior to activated vitamin D analogs in
reducing PTH levels; (iii) currently available evidence from
RCTs suggests that nutritional vitamin D is ineffective in im-
proving several intermediate endpoints, such as aortic stiffness,
LVMI, epoetin utilization, immune function, functional cap-
acity and health-related quality of life; and (iv) in the absence
of adequately powered RCTs, it remains unclear whether nutri-
tional vitamin D supplementation improves survival and re-
duces cause-speciﬁc morbidity and mortality in people with
CKD and ESRD. Correction of secondary hyperparathyroidism
and improvement in outcomes and not simply hypovitamino-
sis D are the major targets of therapy for the beneﬁt of our pa-
tients. There is little evidence to support the practice of
nutritional vitamin D use in CKD. We believe that VDRA
use is evidence-based and should replace nutritional vitamin
D use in CKD.
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I am very impressed to see a fresh meta-analysis frommy learn-
ed and expert opponent, delivered just for this debate.
However, I am very concerned that such activities can be
misleading.
What is needed is two things—ﬁrst, a decent set of trials.
This must involve ﬁrst some preparatory ‘dose ranging’
work, to see how responsive plasma parathyroid hormone
(PTH) is to the administration of natural vitamin D com-
pounds. This would be akin to phase 2 work in preparing a
regulatory submission for drug approval. It is important to
understand that the impact of daily, weekly, monthly and
3/12ly oral (or im) supplements need to be considered separ-
ately—these cannot be assumed to produce the same outputs.
The stimulation of counter-regulatory enzymes to degrade
1,25 di(OH)vitamin D3 is much greater with higher doses,
and, with intermittent boluses. Also, we need to know whether
to aim for simple repletion (so, >75 nmol/L), or to aim a little
higher than that. We simply don’t know yet [1].
In addition, and more worrying still to me, is the simplistic
assumption that all people respond, and to the same extent. The
reality of all treatment, especially in a more diverse recipient
population, is that you might see, and have to tease out, ‘re-
sponder’ versus ‘non-responder’ populations. This would of
course apply to any form of vitamin D compound used in
this clinical situation. This type of analysis is of course de-
stroyed by simplistic ‘yes or no’ metrics, so beloved of many
in this ﬁeld.
Finally, we do not actually know the real PTH range to aim
for (we know what is too low, probably, and, what is too high,
probably). This is akin to the correction of low hematocrit using
erythropoiesis-stimulating agents in renal anemia. This is a ser-
ious problem, as also is the sole reliance on a most unreliable
biomarker, PTH, in our trials and interventions [2].
Until we truly know what we are doing in a rather complex
biological situation, we would be better advised to attempt gen-
tly holistic vitamin D repletion with natural compounds which
then require activation. If these fail, as judged by reasonable and
reliable tests of success, then it may need the addition of more
powerful, more toxic, and more expensive treatments. This I
feel is especially the case in the context of chronic kidney dis-
ease, not yet requiring dialysis.
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